Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Gene Sequencing Software Could Aid in Early Detection, Treatment of Cancer

By Johns Hopkins University | March 1, 2017

The researchers used this nanopore sequencing device and new software to find DNA methylation marks that have been linked to cancer and other illnesses. Source: Will Kirk/Johns Hopkins University

A research team from the United States and Canada has developed and successfully tested new computational software that determines whether a human DNA sample includes an epigenetic add-on linked to cancer and other adverse health conditions.

In the Feb. 20 issue of the journal Nature Methods, team members from Johns Hopkins University, the Ontario Institute for Cancer Research and the University of Toronto detailed their promising new method of detecting the presence of an extra mark on DNA called cytosine methylation.

Cytosine is one of the four main genetic building blocks, or nucleotides, that make up DNA. Methylation simply refers to the presence of a biochemical (methyl) group attached to a nucleotide, in this case cytosine. This altered version of cytosine can affect the way important genes are switched on or off. Such genetic miscues can play havoc with healthy activity within cells.

Examining these marks is important to researchers who are trying to pin down methylation’s precise role in various health problems. But current methods of mapping methylation each have stubborn shortcomings, such as harsh handling of the DNA sample and the need to use particularly large and pre-treated tissue samples.

The new software described in Nature Methods is used with a commercially available nanopore sequencing device. The authors say this technique will directly characterize DNA methylation from smaller tissue samples. “We show that with careful analysis of nanopore sequencing data we can extract this extra layer of information,” said lead author Jared T. Simpson, a principal investigator in the Informatics and Bio-computing Program at the Ontario Institute for Cancer Research and an assistant professor of computer science at the University of Toronto.

The international team’s software is designed to work with an Oxford Nanopore Technologies MinION sequencer, roughly the size of a large USB thumb drive. When this unit is used, DNA is pulled through 512 extremely small holes, as an electric current passes through. Distinctive changes in the current as the DNA moves through the hole allow the software to identify the sequence of the DNA, and now the methylation marks on the DNA as well.

In the Nature Methods paper, the researchers said they first used synthetically methylated DNA to “train” their software to distinguish between methylated cytosine and cytosine that lacks the crucial biochemical attachment.

Team members then tested the software process on DNA samples derived from human breast cancer cells and successfully detected changes in methylation between cancer and normal samples.

“This technique can read long pieces of DNA and see changes in the extent of methylation in the sample,” said Winston Timp, an assistant professor of biomedical engineering at Johns Hopkins who supervised the research and was senior author of the journal article. “It let us look at how the changes in methylation appear on individual molecules as they pass through this pore.”

Such information is important, the researchers say, because faulty methylation is believed to play a role in birth defects and diseases such as rheumatoid arthritis, as well as cancer. “We already know,” Timp said, “that methylation changes show up early in the development of cancer.”

He said more information about DNA methylation could be helpful in devising new ways to detect cancer at an earlier stage and developing new treatments that are targeted more precisely to a patient’s genetic makeup.

To help advance such research, the team members have made their nanopore sequencing software for detecting DNA methylation available on a free open-source basis at https://github.com/jts/nanopolish.

“We’ve taken this line of research a critical step further ahead,” Timp said. “My hope is that others in this field will begin using the software right away.”

“Congratulations to team members from Johns Hopkins University, the Ontario Institute for Cancer Research and the University of Toronto on their new gene sequencing software and findings,” said Reza Moridi, Ontario’s minister of research, innovation and science. “These new insights into DNA methylation could help lead to new and innovative ways to detect and treat cancer.”


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE